{
  "id": 20220663,
  "title": "Which Healthcare ETF Is the Better Buy: VanEck’s Pharma Fund PPH or iShares’ Biotech Fund IBB?",
  "url": "https://urgent.news/2026/11/15/which-healthcare-etf-is-the-better-buy-vanecks-pharma-fund-pph-or",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-15T19:16:33.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/etfs/2026/11/15/which-healthcare-etf-is-the-better-buy-vaneck-s-pharma-fund-pph-or-ishares-biotech-fund-ibb/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Investors are debating between VanEck Pharmaceutical ETF (PPH +1.11%) and iShares Biotechnology ETF (IBB -0.44%) when considering targeted exposure to the healthcare industry. While both offer specific investments, they exhibit distinct risk-reward profiles. The VanEck fund focuses on a concentrated portfolio of 26 large, dividend-paying drugmakers, whereas the iShares fund provides broader diversification across 243 holdings, including 87% in biotechnology and 10% in life sciences. PPH's largest positions include Eli Lilly (LLY +1.26%), Merck & Co (MRK +0.55%), and Novo Nordisk (NVO +2.41%). In contrast, IBB's leading companies are Gilead Sciences (GILD +0.08%), Amgen (AMGN -0.30%), and Vertex Pharmaceuticals (VRTX -0.74%). VanEck has a lower expense ratio (0.36%) and delivers a higher dividend yield (1.8%) compared to iShares' (0.2%). PPH's steadier performance over five years is also notable, with a smaller worst drop than IBB's. Investors may find PPH more appealing due to its broader, more stable exposure to the healthcare sector and higher dividend payouts.",
  "summary": "One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.",
  "key_points": [
    "VanEck PPH invests in 26 large, dividend-paying drugmakers",
    "iShares IBB offers broader diversification across 243 holdings",
    "PPH has lower expense ratio (0.36%) and higher dividend yield (1.8%)"
  ],
  "editors_take": null,
  "illustration": "https://urgent.news/ill/20220663.png",
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Which Healthcare ETF Is the Better Buy: State Street’s Pharma Fund XPH or iShares’ Biotech Fund IBB?",
        "url": "https://urgent.news/2026/11/15/which-healthcare-etf-is-the-better-buy-state-streets-pharma-fund-xph-20215724",
        "published": "2026-11-15T18:39:54.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}